Ascendis Pharma A/S
ASND
$209.05
$8.554.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.62% | 62.54% | 30.00% | 56.16% | 38.23% |
| Total Depreciation and Amortization | -2.29% | 3.52% | -1.59% | -11.69% | -6.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -4.27% | -- |
| Total Other Non-Cash Items | 185.17% | 26.14% | -70.49% | -10.59% | -199.51% |
| Change in Net Operating Assets | -67.94% | -195.00% | 182.64% | -300.02% | 854.78% |
| Cash from Operations | 104.08% | 87.37% | 86.34% | -103.24% | 54.54% |
| Capital Expenditure | 88.79% | -1,237.49% | -242.50% | -758.70% | 47.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -99.47% | -100.00% |
| Cash from Investing | 88.79% | -852.34% | -109.52% | -105.72% | -102.29% |
| Total Debt Issued | -- | -- | -- | 100.00% | -4.02% |
| Total Debt Repaid | -133.68% | -94.57% | -10.05% | -7.75% | -7.41% |
| Issuance of Common Stock | -84.68% | 3,315.89% | -34.77% | 1,006.29% | 4,687.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.34% | 399.84% | -194.84% | 101.42% | 201.47% |
| Foreign Exchange rate Adjustments | 198.43% | -1,354.50% | -303.90% | 394.45% | -172.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -86.94% | 59.09% | 43.91% | -33.03% | 687.55% |